GAO Finds Universal Naloxone Coverage But Gaps in High-Potency Countermeasures
A GAO report reveals comprehensive access to standard naloxone across Medicare Part D and Medicaid, but highlights significant cost barriers and coverage gaps for newer over-the-counter formulations and high-potency countermeasures like nalmefene.
A comprehensive review by the Government Accountability Office (GAO) indicates that while federal health programs maintain widespread coverage for standard opioid overdose reversal medications, structural cost barriers and formulary restrictions persist for newer, high-potency formulations. The analysis examined Medicare Part D data for 2025 and state Medicaid drug reimbursement metrics for 2024, confirming that all enrollees across both programs had access to at least one form of naloxone. However, coverage for nalmefene—a longer-acting agent designed to combat synthetic opioids—was substantially less common across state and federal formularies.
Financial structures vary dramatically based on delivery mechanisms and prescription status. GAO found that generic injectable naloxone remains the most accessible option, carrying median copays between $3 and $10 for Medicare Part D participants. Conversely, brand-name nasal sprays and high-dose variants require coinsurance rates ranging from 25 to 35 percent, requiring out-of-pocket payments of up to $53 for a single $150 dose. While selected state Medicaid programs eliminated copays entirely, others maintained low cost-sharing tiers. Crucially, the transition of low-dose naloxone nasal sprays to over-the-counter (OTC) status since 2023 has introduced regulatory friction, as traditional insurance frameworks frequently exclude non-prescription therapeutics from coverage.
For defense, intelligence, and civilian government leaders, these findings highlight critical considerations for force health protection and federal healthcare administration. Substance use disorders and synthetic opioid exposure present operational readiness risks across military installations, defense industrial base workforces, and veteran communities. The cost and coverage dynamics identified by GAO directly parallel challenges faced by the Defense Health Agency (DHA) and TRICARE in structuring pharmaceutical formularies. Ensuring seamless access to potent countermeasures like nalmefene is increasingly vital as synthetic opioids dominate the public health threat landscape.
To maintain operational resilience, government program managers and policy officials must address the administrative policy gaps surrounding OTC drug coverage and standardize low-barrier access across federal health systems. Meanwhile, healthcare contractors and pharmaceutical logistics suppliers must prepare for shifting federal acquisition priorities that balance cost containment against emergency medical readiness demands. Navigating these formulary structures will be essential for sustaining workforce health across the national security enterprise. (Source: GAO Reports)
Executive takeaway
Subscribe to receive signals like this — plus the executive analysis behind them.
Get the Signals